SCHEMBL18930795

SCHEMBL18930795

CC(C)(C)OC(=O)N1CCC2(c3ccc(C#N)cc3)OC2C1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 6/20 0.49
JAK2 O60674 1/20 0.42
JAK1 P23458 1/20 0.42
GPR183 P32249 1/20 0.42
AR P10275 1/20 0.41
EGLN2 Q96KS0 2/20 0.40
ALDH1A1 P00352 2/20 0.39
CYP3A4 P08684 1/20 0.39
MAPK1 P28482 1/20 0.39
CYP2C19 P33261 1/20 0.39
HSD17B10 Q99714 1/20 0.39
MEN1 O00255 1/20 0.39
MAPT P10636 1/20 0.39
KMT2A Q03164 1/20 0.39
PDK1 Q15118 1/20 0.39
PDK2 Q15119 1/20 0.39
PDK3 Q15120 1/20 0.39
PDK4 Q16654 1/20 0.39
IRAK4 Q9NWZ3 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL652900 0.87 MEN1 (0.48) ALDH1A1HSD17B10MEN1KMT2A
SCHEMBL21144713 0.82 TSHR (0.39) ALDH1A1CYP3A4MAPK1CYP2C19HSD17B10
SCHEMBL14256120 0.81 GPR119 (0.42) GPR119GPR183MEN1KMT2A
SCHEMBL5241788 0.80 GPR119 (0.54) GPR119JAK2JAK1EGLN2ALDH1A1
SCHEMBL5462841 0.79 GPR119 (0.53) GPR119JAK2JAK1EGLN2ALDH1A1
SCHEMBL18930796 0.77 GPR119 (0.47) GPR119JAK2JAK1GPR183EGLN2
SCHEMBL16267800 0.77 ALDH1A1 (0.47) ALDH1A1MEN1KMT2A
SCHEMBL18432564 0.77 GPR119 (0.51) GPR119JAK2JAK1EGLN2ALDH1A1
SCHEMBL31649333 0.76 GPR119 (0.48) GPR119JAK2JAK1ARALDH1A1
SCHEMBL12489308 0.76 GPR119 (0.50) GPR119JAK2JAK1EGLN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10654818-B2 Furane derivatives as inhibitors of ATAD2 BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2020-05-19 US disclosed
US-10654818-B2 Furane derivatives as inhibitors of ATAD2 BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2020-05-19 US disclosed
EP-3383865-B1 FURANE DERIVATIVES AS INHIBITORS OF ATAD2 Bayer Pharma AG (DE) 2020-01-29 EP disclosed
EP-3383865-B1 FURANE DERIVATIVES AS INHIBITORS OF ATAD2 Bayer Pharma AG (DE) 2020-01-29 EP disclosed
US-20190218196-A1 FURANE DERIVATIVES AS INHIBITORS OF ATAD2 BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2019-07-18 US disclosed
US-20190218196-A1 FURANE DERIVATIVES AS INHIBITORS OF ATAD2 BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2019-07-18 US disclosed
WO-2017093272-A1 FURANE DERIVATIVES AS INHIBITORS OF ATAD2 BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-06-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190218196-A1 FURANE DERIVATIVES AS INHIBITORS OF ATAD2 ATAD2, ATAD2B, TAF1L GPR119 3552/4885JAK2 4529/4885JAK1 4099/4885
US-10654818-B2 Furane derivatives as inhibitors of ATAD2 ATAD2, ATAD2B, TAF1L GPR119 3552/4885JAK2 4529/4885JAK1 4099/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.